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Abstract
Recent multi-dimensional approaches to the study of complex disease have revealed powerful insights into how genetic
and epigenetic factors may underlie their aetiopathogenesis. We examined genotype-epigenotype interactions in the
context of Type 2 Diabetes (T2D), focussing on known regions of genomic susceptibility. We assayed DNA methylation in 60
females, stratified according to disease susceptibility haplotype using previously identified association loci. CpG methylation
was assessed using methylated DNA immunoprecipitation on a targeted array (MeDIP-chip) and absolute methylation
values were estimated using a Bayesian algorithm (BATMAN). Absolute methylation levels were quantified across LD blocks,
and we identified increased DNA methylation on the FTO obesity susceptibility haplotype, tagged by the rs8050136 risk
allele A (p= 9.4061024, permutation p= 1.061023). Further analysis across the 46 kb LD block using sliding windows
localised the most significant difference to be within a 7.7 kb region (p= 1.1361027). Sequence level analysis, followed by
pyrosequencing validation, revealed that the methylation difference was driven by the co-ordinated phase of CpG-creating
SNPs across the risk haplotype. This 7.7 kb region of haplotype-specific methylation (HSM), encapsulates a Highly Conserved
Non-Coding Element (HCNE) that has previously been validated as a long-range enhancer, supported by the histone
H3K4me1 enhancer signature. This study demonstrates that integration of Genome-Wide Association (GWA) SNP and
epigenomic DNA methylation data can identify potential novel genotype-epigenotype interactions within disease-
associated loci, thus providing a novel route to aid unravelling common complex diseases.
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Introduction
Type 2 diabetes (T2D) and obesity are complex diseases with
polygenic susceptibility. Recent genome wide association (GWA)
studies have provided significant insight towards gene discovery
and, to date, around 30 common variant loci have been associated
with T2D [1,2]. Despite these important advances, known genetic
variants explain ,10% of the heritable component of disease, and
little is known about their contribution to aetiology. Ongoing
studies are attempting to explain this ‘missing heritability’ in
complex diseases via the detection of rare and structural variants,
interactions between discovery SNPs and causal variants, and
identification of associated stable epigenetic modifications [3].
Environmental determinants of these complex diseases are well-
characterised by a wealth of epidemiological literature [4] but
much less is understood about their mechanistic role or interaction
with genetic susceptibility. Epigenetic mechanisms regulate gene
expression, may be induced via environmental agents and can be
inherited through somatic or germline pathways [5]. Genome-
wide epigenetic reprogramming occurs during gametogenesis,
implicating early fetal development as a period susceptible to this
environmental influence. Strong evidence in humans and rodents
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implicates in utero fetal nutritional deficiency with adult-onset
chronic diseases including T2D [6,7]. Furthermore, differentially
methylated regions (DMRs) of genes of relevance to T2D have
been identified in individuals prenatally exposed to famine [8].
Epigenetic variability, set at an extremely early development stage,
permeates through all three subsequently developing germ layers
[9], thereby facilitating possible identification in mesoderm-
derived blood.
An epigenomic approach may provide insight into the genetic,
epigenetic and environmental factors underlying the aetiology of
complex diseases. The potential for interaction between these
factors is increasingly understood, however the relationship
between specific epigenetic modifications and genomic features,
whether independent or dependent, is poorly explained in the
context of disease and phenotype. In contrast, the role of aberrant
epigenetic marks is well established at single gene loci with rare
imprinted disorders [10] and as well in cancer genomes with global
hypomethylation and locus hypermethylation [11]. Recent
investigations in other complex diseases, such as Systemic Lupus
Erythematosus with discordant monozygotic twins [12] and Type
1 diabetes with imprinted common susceptibility [13], have been
successful. A range of new technology platforms and bioinformatic
tools now exist with which to test hypotheses around these putative
interactions. The developmental and environmental origins of
T2D suggest a potential role of programmed and/or stochastic
epigenetic processes in determining disease risk that could arise
during early embryonic development and are identifiable in a
range of tissues. We hypothesize that genotype-epigenotype
interactions may underlie the aetiopathogenesis of T2D, as a
complex disease, and use an integrated platform with which to
investigate their occurrence. We applied methylated DNA
immunoprecipitation (MeDIP) to fragmented genomic DNA
sampled from participants with and without T2D-risk genotypes.
Enriched fragments were hybridised against total input DNA on a
Nimblegen 385k array, encompassing known regions of genetic
susceptibility to T2D (regions identified from previous locus and
genome-wide association analyses; monogenic T2D and obesity
genes and related disorders (as of 2008) (see Supplementary Table
S1 for full list). With each array tiling.21 Mb, a total of.1.2 Gb
of sequence was subsequently statistically assessed for DNA
methylation status. By combining genotype with methylation
status, an investigation for allele- [14] or haplotype-specific effects
and hepitypes [15,16,17] could be made to understand the
potential sources of methylation variability at these genomic
locations.
Results
We determined DNA methylation differences on DNA derived
from peripheral whole blood from 60 Caucasians, comprising 30
with Type 2 diabetes (UK Warren 2 T2D case sample) and 30
without T2D (Exeter Family Study of Childhood Health). An all-
female set was used to remove any confounding effect of sex.
DNA Methylation Analysis within T2D Association SNP LD
Blocks
MeDIP-chip was performed on individual samples to quantify
DNA methylation. The relationship between genetic haplotypes
and DNA methylation at the genomic regions covered by the
microarray was estimated by summating the methylation scores,
estimated by the BATMAN algorithm, across each T2D
association SNP LD block (as defined by Gabriel et al. [18]), and
calculating an average ‘methylation load’ for all 60 individuals.
Individuals then were grouped into three genotypic sets by their
respective genotype for each T2D-association SNP (or tagging
SNP in perfect LD with association SNP). Kruskal-Wallis and
Linear Regression analyses were performed to determine the
relationship between genotype and average methylation score.
Uncorrected p-values for the Linear Regression analysis are shown
in Table 1.
Sliding Windows and Permutation Methylation Analysis
of the FTO LD Block
In our integrated epigenomic-genomic analysis, the large 46 kb
LD block of the FTO gene (Supplementary Figure S1) was the only
locus to reach nominal statistical significance by Kruskal-Wallis
analysis (p=0.014). We performed a permutation analysis, in
which the genotype assignment and observed methylation scores
were shuffled 10,000 times, achieving a significant empirical p-
value of 0.012. Subsequent analysis by Linear Regression was
highly significant with p=9.4061024, and empirical p-value
calculation by 10,000 permutations of 1.061023. Age was
included as a factor in this later analysis, as methylation changes
due to age are significant in certain loci [19,20,21], but was
excluded as a significant confounder (p=0.676). We also
performed linear regression analysis for the other tested loci and
did not find any association between age and methylation (data
not shown). FTO SNP rs8050136 risk allele A homozygotes were
shown to have a higher average level of methylation of 0.531, with
heterozygotes at an intermediate level at 0.510 and G homozy-
gotes with 0.497 (Table 2). Of note, although the initial association
for FTO with BMI was identified by SNP rs9939609 [22],
numerous subsequent studies have used different SNPs, all of
which capture the same common haplotype (HapMap CEU
frequency = 0.425 (Figure 1)). This LD Block encompasses just
under half of the first intron, exon 2 and the beginning of
the second intron of the major FTO isoform (Supplementary
Figure S1).
To investigate whether this methylation difference was being
driven by a distinct region within the 46 kb LD block, and if so, to
isolate its location, a sliding windows analysis utilising BATMAN
methylation scores (estimated in 100 bp windows) was performed.
The sliding windows analysis uses a computational approach to
move different window sizes across each LD block, starting with a
window size of 1 (100 bp), increasing iteratively by one on each
pass, up to the maximum window number of 334 (Supplementary
Videos S1 and S2). A central peak of methylation difference was
most prominent in the 9 window (900 bp wide, at windows 161–
169, chr16:52,378,500-52,379,399) analysis with Kruskal-Wallis
p=5.63061025, empirical p=,161025 with 10,000 permuta-
tions and Linear Regression analysis p=1.9461025 (Figure 2).
Methylation averages were again highest for the A homozygotes
(AA 0.603, AC 0.564, CC 0.507). In addition, plotting the slope of
linear regression analysis for the 9 window across the LD block
indicated that the p-value peaks all co-locate with the same
negative regression slope peaks. From these findings, we infer that
all of these regions could be contributing, with varying strength, to
the increased methylation signal (Supplementary Figure S2).
The strongest association between methylation and genotype
was identified with a larger window size of 60 (7.7 kb, after
exclusion of repeat regions, - windows 110–169, chr16:52,371,
700–52,379,399) with Kruskal-Wallis p=8.6961026, empirical
p=,161025 with 10,000 permutations, Linear Regression
analysis p=1.3361027 (Figure 3) and age p=0.444. This 7.7 kb
window becomes most significant just at the point when it
encapsulates the 900 bp window at its downstream edge. The
same trend in the average methylation scores was again identified
(AA 0.529, AC 0.503, CC 0.478, Figure 4). The sliding windows
FTO Haplotype DNA Methylation
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analysis was also performed across the other T2D association LD
blocks, but none showed any significant increasing p-values with
window sizes greater than 10 (1 kb) (data not shown).
The findings at the FTO LD block, using an integrated
epigenomic-genomic analysis, give a strong estimate of the
relationship between haplotype and DNA methylation level.
Since this approach is calculated by statistically-derived
methylation estimates in 100 bp windows, it is unable to define
the actual methylation state neither of individual CpG sites nor
their relationship to SNPs. We therefore proceeded to investi-
gate the genetic and epigenetic architecture of the 900 bp peak
window to explore the exact methylation differences driving this
signal.
Investigation of the Genetic Architecture Underlying the
900 bp Window Peak
The central 9 window peak of 900 bp contains only seven CpG
sites in the reference sequence, although of the eight common
SNPs within the same region, three create or abrogate additional
CpG sites (being YpG or CpR SNPs, IUPAC: Y=C or T, R=G
or A). These SNPs (rs7206629, rs7202116 and rs7202296) were all
included in the AFD-EUR European panel (dbSNP). In this
dataset they all possess identical minor allele frequencies (MAFs)
implying high likelihood of residing on the same haplotype
(Table 3). Only rs7202116 is included in the HapMap CEU data
set, and the methylated state allele, G of a CpG, is present on the
susceptibility haplotype (Figure 1), and is in absolute and near-
perfect LD with the susceptibility SNPs identified (Table 4).
Therefore those with the obesity-susceptibility haplotype would
possess ten CpG sites capable of methylation, compared with
seven, within this peak region.
Validation of Methylation Differences by Pyrosequencing
Methylation differences identified between the susceptibility and
non-susceptibility haplotypes were validated and quantified using
bisulphite-pyrosequencing on 80 samples, using the initial 60 plus
an additional 20 samples from the same studies. Within the 900 bp
window, four CpGs were investigated, located at the downstream
end of the 7.7 kb peak, and included one of the SNP dependent
CpGs (rs7202296). An additional six CpGs that lie directly
beneath the broad 7.7 kb peak, including one SNP dependent
CpG (rs11075988) were examined. The common SNP distribution
within the 7.7 kb region, which includes the 900 bp peak, is
detailed in Supplementary Figure S4.
Methylation levels at the cytosine adjacent to rs7202296 (CpR)
were, as expected, completely dependent on the presence of its
CpG conformation, with average methylation levels of 87% for A
Table 1. Average Methylation in Association SNP LD blocks by Genotype.
Average Methylation
Chr LD Block Genotyped SNP Gene/Locus 11 12 22 p-value
1 120236149 120398430 rs29343811 NOTCH2 0.496 0.495 0.502 0.187
2 43529937 43617946 rs7578597 THADA 0.492 0.512 0.504 0.564
3 12298413 12372392 rs1801282 PPARG 0.512 0.509 0.511 0.640
3 64673853 64705161 rs4607103 ADAMTS9 0.477 0.472 0.481 0.760
3 186971576 187031377 rs4402960 IGF2BP2 0.502 0.493 0.502 0.016
4 6317902 6363877 rs10010131 WFS1 0.581 0.604 0.590 0.982
7 28147081 28175361 rs864745 JAZF1 0.501 0.492 0.494 0.317
8 118252732 118254914 rs13266634 SLC30A8 0.333 0.350 0.303 0.865
9 22122209 22126489 rs10811661 CDKN2A/CDKN2B 0.543 0.512 0.512 0.389
10 12367941 123680402 rs12779790 CDC123/CAMK1D 0.611 0.590 0.671 0.913
10 94426831 94467199 rs1111875 HHEX/IDE 0.480 0.483 0.483 0.369
11 17350649 173652063 rs52194 KCNJ11 0.501 0.502 0.498 0.540
12 69942990 69949369 rs7961581 TSPAN8 0.457 0.461 0.470 0.289
16 52357008 52402988 rs8050136 FTO 0.497 0.510 0.531 9.39791024
17 33170413 33182480 rs757210 HNF1B 0.423 0.430 0.427 0.382
P-values are calculated by Linear Regression and are shown uncorrected (11 – homozygote common, 12 – heterozygote, 22 – homozygote rare allele).
a) r2 = 1 with rs10923931,
b) Not in LD block – single BATMAN window of 100 bp utilised,
c) LD block of associated SNP rs5215 used as rs5219 not typed in HapMap, r2 = 0.995 with rs5219. Methylation is given as average BATMAN scores across regions (0 =
unmethylated, 1 = fully methylated).
doi:10.1371/journal.pone.0014040.t001
Table 2. Average Methylation by rs8050136 Genotype.
FTO LD Block
(46 kb)
Broad Peak
(7.7 kb)
Narrow Peak
(900 bp)
Region 52,357,008–
52,402,988
52,371,700–
52,379,399
52,378,500–
52,379,399
AA 0.531 0.529 0.603
AC 0.510 0.503 0.564
CC 0.497 0.478 0.507
p-value 9.39761024 1.13361027 1.9461025
Results shown for the entire LD block, the Broad 7.7 kb 60-window peak
(Figure 3) and the Narrow 900 bp 9-window peak (Figure 2). Methylation is
given as average BATMAN scores across regions (0 = unmethylated, 1 = fully
methylated).
doi:10.1371/journal.pone.0014040.t002
FTO Haplotype DNA Methylation
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homozygotes, 55.7% for AC heterozygotes and 11.5% for C
homozygotes, with respect to rs8050136 genotype (Table 5). On
examination of the sequence information from the pyrosequencing
data, due to non-perfect LD between rs8050136 and rs7202296,
one individual homozygous for the A rs8050136 allele was in fact
homozygous CpA and another was heterozygote. Excluding these
two individuals, the methylation level was 98.6% for those who
were truly genetically CpG at rs7202296. The additional cytosines
examined within this window did not show differences that could
be accounted for by allele-specific methylation (ASM) or the
presence of a hepitype, whereby a cis-methylation effect on the
surrounding non-polymorphic CpG’s methylation state would
have been observed [15]. Of note is the ,50% methylation values
of the cytosine at 52,379,254, implying that whilst no evidence of
ASM, there may be parent-of-origin specific methylation imprint-
ing of this CpG, although FTO is not known to be imprinted [23].
The three in-phase CpG-creating SNPs could easily account on
their own for the ,10% difference seen in methylation levels in
the 900 bp window peak identified in the initial MeDIP-array.
The additional CpGs beneath the peak of Window 60, also
showed methylation changes associated with a CpR site at
rs11075988. At this SNP, the allele that abrogated the ability to
methylate was in LD with the rs8050136 susceptibility genotype A,
i.e. it was on the alternate phase. Decreased methylation of this one
SNP is therefore vastly outweighed by the rest of the haplotype.
The additional six CpGs showed methylation percentages for AA,
AC and CC genotypic groups respectively of 77.6, 72.8, 76.7
(16:52377247), 92.7, 92.0, 90.8 (16:52377254), 9.5, 38.4, 69.0
(16:52377271, rs11075988 dependent), 96.7, 98.5, 98.8
(16:52377279), 82.6, 78.4, 81.1 (16:52377282), and 87.4, 85.9,
84.9 (16:52377308).
Replication of Findings in Central Nervous Tissue
Finally, we used the same bisulphite-pyrosequencing assays to
determine whether methylation differences within the 900 bp
window peak were displayed in tissues which show high FTO
expression and have a role in central energy balance. We studied
14 healthy brain samples (4 hypothalamus and 10 prefrontal
cortex) and replicated the same findings at the CpG-creating SNPs
described above. We did not see any allele-specific effects on the
surrounding CpG sites.
Evolutionary Analysis
Examination of the three critical CpG-creating SNPs within the
narrow peak (rs7206629, rs7202116 and rs7202296) revealed that
the latter two have transitioned from CpA to CpG, gaining the
ability to methylate from the ancestral state (identical in Pan
Troglodytes, Pongo pygmaeus and Macaca mulatta, Table 6). This
mutational event is rarer than the reverse transition by
deamination of the methylated cytosine [24], and identical
frequency of both SNPs are seen in three ethnicity panels
(Table 3). Analysis of dbSNP data (release 129) indicated that
whilst ,60% of 193,133 validated SNPs on chromosome 16, with
known ancestral state, occur at a CpG site, only ,12% of them
have gained the ability to methylate since their common ancestor
and less than 0.5% lie within at least 75 bp of each other, as per
Figure 1. Haplotypes for FTO Susceptibility LD Block from HapMap CEU. BMI Association-SNPs are in red boxes for the respective studies.
SNPs 08 (rs1421085) & 34 (rs17817449) – Dina et al. [33], SNP 39 (rs8050136) – Scott et al. [34], SNP 44 (rs3751812) – Grant et al. [65], SNP 50
(rs9939609) – Frayling et al. [22], SNP 67 (rs9930506) – Scuteri et al. [35]. *The SNP rs8050136 genotypes were used as the haplotype tagging SNP for
this study’s subjects. SNP 52 – (rs7202116 blue box) is CpG-creating or abrogating dependent upon which allele is present and resides within the
900 bp window peak.
doi:10.1371/journal.pone.0014040.g001
FTO Haplotype DNA Methylation
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rs7202116 and rs7202996. Furthermore, rs7202116 is located
within a short 49 bp mammalian evolutionarily constrained
element (Chr16:52,379,085–52,379,132) as identified by Genomic
Evolutionary Rate Profiling (GERP) [25] of 31 eutherian
mammals.
We analysed the 420 HapMap Phase II phased SNP haplotypes
for CEU, YRI and ASN and found that this region comprises 60
unique haplotypes. A Median-Joining Network analysis [26,27]
(Supplementary Figure S3) was performed, including an inferred
ancestral haplotype, which indicated that the susceptibility
haplotype is closer to, or less mutational events away from, this
ancestral haplotype. This finding suggests that the ability to
methylate was gained early, is maintained on the susceptibility
haplotype, and has been lost in the younger haplotypes present in
humans. However no haplotypic evidence of selection was
apparent (XP-EHH [28] or iHS [29], data not shown), although
these tests are more powerful for more recent mutational events.
Enhancer Activity Evidence within the 7.7 kb Region
A ChIP-chip study, using the same T2D array as part of a larger
experiment, investigated normal skeletal muscle cells and identi-
fied evidence of enhancer activity within the 7.7 kb window, with
the classic signature of H3K4me1 and no other strong signal
(Supplementary Figure S4). These findings are consistent with
those of Ragvin et al. who have recently identified long range
enhancers within the first intron of FTO that influence the
expression of IRX3, located ,470 kb downstream of this region.
[30]. One of the two critical Highly Conserved Noncoding
Elements (HCNEs) proposed to affect IRX3 expression by
enhancer activity that overlaps with risk variants, designated as
element 6 by Ragvin et al. is located at Chr16:52,377,745–
52,378,287, and resides centrally within the broad 7.7 kb peak
(Figure 3). This 542 bp element is also only 213 bps 59 of the
900 bp window.
Expression Analysis
Direct analysis of allele-specific expression of FTO mRNA is not
possible as no common coding polymorphisms exist within the LD
block, or rest of the gene. Examining the Sanger GENEVAR
HapMap CEU expression data identified no significant differences
with respect to FTO haplotype status in FTO or IRX3 expression
from lymphoblastoid cell lines in children or adults [31] (data not
shown). We also used an available RNA-Seq dataset derived from
the cerebellum of six male individuals [32], but were unable to
identify allele-specific expression of FTO (by attempting to utilise
any pre-mRNA intronic reads that may be present) or IRX3. This
was due lack of informative SNPs in former and low coverage
across the latter.
T2D versus non-T2D analysis
We also compared individuals with and without T2D, as a case-
control analysis, across all the assayed regions of the array, (T2D
and obesity related phenotype candidates, 1q linkage region and
imprinted regions). We did not identify any disease-related
differently methylated regions (DMRs) of statistical significance
post false discovery rate correction (data not shown). The average
Figure 2. Linear Regression for Methylation with respect to Genotype for 9 Window. Linear regression p-values (-log 10) for a sliding
window of 9 BATMAN windows across the FTO LD susceptibility block (Chr16:52,357,008–52,402,988)
doi:10.1371/journal.pone.0014040.g002
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of the variance and standard deviation in methylation level for all
60 individuals across the entire MeDIP data set was 0.02 and 0.14,
respectively.
Discussion
Epigenomic factors, including DNA methylation, histone
modifications and non-coding RNAs, are an integral link between
DNA sequence variation and subsequent transcriptional output
modulation. Increased understanding of these elements will be
crucial to obtain a coherent functional assessment of the large
number of non-coding DNA variants identified from contempo-
rary whole genome sequencing case-control studies, and to
delineate their developmental and tissue-specific features and
constraints.
This study investigated the DNA methylation state of genomic
loci with evidence for involvement with T2D and found an
association with the susceptibility locus that resides within the FTO
gene. This region was identified in a T2D GWA Study, with a
common haplotype located across intron 1, exon 2 and intron 2
captured equivalently by various SNPs, subsequently shown to be
mediating its disease susceptibility effect through obesity
[22,33,34,35]. Murine models initially lent support to FTO itself
being the causal gene in the locus; an obesity protective phenotype
was observed in the fto knock-out mouse [36] and a similar but
lesser effect in the hypomorphic fto missense I367F mutant [37]. A
loss-of-function mutation in FTO was recognised in humans as an
autosomal-recessive lethal syndrome (OMIM #612938) with a
phenotype of multiple malformations and severe growth retarda-
tion, with non-obese heterozygote relatives [38]. Attempts to
identify expression differences in FTO in human skeletal muscle
and subcutaneous adipose tissue with respect to risk SNPs have
been unsuccessful to date [39] and no evidence of allele-specific
expression in immortalised lymphoblastic cell lines has been
established [40]. Subsequently Meyre et al. identified further FTO
heterozygous, loss-of-function mutations in obese as well as lean
subjects, further clouding FTO’s causative role [41] and illustrating
the complexity of interpreting the function of this dioxygenase in
energy balance [42].
Identification of stable epigenetic modifications may aid the
exploration of genotype-phenotype interactions in complex
diseases. DNA methylation can exert its functional influence
through a range of different processes, including direct effects on
transcription factor binding, or indirectly via changes to post-
translational histone packaging and modulation of chromatin
conformation and function [43]. The ability to detect these
epigenetic influences will depend on their direct association with
genotypic factors and will therefore range from obligatory to
stochastic [44]. Thus we have utilised the power of the large scale
GWA studies to look for genotype-methylation state associations.
We have identified a methylation association with the strongly
replicated disease haplotype of the FTO gene, tagged by SNP
rs8050136. Therefore the association identified is with the
individuals’ genotypes not their particular phenotype status. We
Figure 3. Linear Regression for Methylation with respect to Genotype for 60 Window. Linear regression p-values (-log 10) for a sliding
window of 60 BATMAN windows across the FTO LD susceptibility block (Chr16:52,357,008–52,402,988). Blue bar indicates location of HCNE enhancer
element 6 from Ragvin et al. [30].
doi:10.1371/journal.pone.0014040.g003
FTO Haplotype DNA Methylation
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e14040
confirmed and validated these results at single-base resolution
within the contributory signal using bisulphite pyrosequencing. In
doing so, we identified that the methylation signal was genetically
led by the phase of three CpG-creating SNPs in LD within a
narrow 900 bp window peak. We did not find evidence of a cis-
methylation or hepitype effect [15,16,17]. The ,10% change
identified in our MeDIP experiment is likely to be an
underestimate in this region as BATMAN calculations are based
upon the reference genome. Additional work in murine strains also
supports the inference that inherited genetic variability is a major
determinate on epigenetic variability [45]. Zhang et al. identified
ASM with as much as 85% difference between alleles across CpG
Islands (CGIs) [46]. However, it is not clear how much of this
effect is driven by CpG-creating SNPs or the additional influence
on surrounding CpG methylation, other genetic polymorphism
effects on the methylation machinery, or a combination of all of
these factors. Shoemaker et al. have recently observed ASM in 23–
37% heterozygous SNPs in differing human cell lines, with 38–
88% of these regions dependent on CpG-SNP variation [47]. We
have termed our findings of a genetically-driven difference in
methylation ability, detected over kilobases, Haplotype-Specific
Methylation (HSM), to differentiate this state from epigenetic
ASM where methylation will vary between alleles at individual
non-SNP CpGs, or a hepitype where genetic variability combines
with ASM within a haplotype. In a similarly designed, but larger
study, the FTO HSM region would be identified as a direct T2D-
DMR.
We did not find an association between risk and non-risk
haplotypes in the other T2D association LD blocks in this
integrated analysis, however this does not exclude the possibility of
more subtle effects in these regions. Although the limitation of the
MeDIP technique is that is does not enable the evaluation of
individual cytosines, it does allow more broad-scale haplotype
methylation differences to be identified, such as those driven by
Figure 4. Box plot of Methylation Scores with respect to Genotype in 7.7 kb Window. Methylation values for Broad Peak within 7.7 kb
window for AA susceptibility homozygote, AC heterozygote and CC homozygote of rs8050136. Linear regression p=1.3361027.
doi:10.1371/journal.pone.0014040.g004
Table 3. Allele Frequencies for CpG-creating SNPs in 900 bp window peak.
SNP Major Minor EUR CHN AFR Ancestral
rs7206629 YpG T C 0.609 0.391 0.833 0.167 0.587 0.413 C
rs7202116 CpR A G 0.609 0.391 0.833 0.167 0.674 0.326 A
rs7202296 CpR A G 0.609 0.391 0.833 0.167 0.674 0.326 A
CpG creating allele given in bold. EUR = European, CHN = Asian, AFR = African American from dbSNP. CpG-creating sites (YpG or CpR SNPs, IUPAC: Y =C or T, R = G or
A).
doi:10.1371/journal.pone.0014040.t003
FTO Haplotype DNA Methylation
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e14040
CpG-SNPs [14,47]. These genetic drivers of ASM can be
identified in easy accessible tissue, which can then be followed
up in the most appropriate disease-related tissue to examine for
any surrounding CpG modulation.
Recent work has hypothesized that the lack of evidence for FTO
expression modulation by susceptibility SNPs may be due to this
region having effects on distal surrounding genes including IRX3
[30] and RBL2 [48]. Ragvin et al. used comparative genomics to
identify HCNEs and overlying genomic regulatory blocks, and
proposed that enhancers in the first intron susceptibility region
exert long range regulatory effects on expression of the
developmental transcription factor gene IRX3, Iroquois Homeo-
box 3 located in a gene desert,170 kb 39 of FTO [30]. Enhancers
are located predominantly in intergenic or intronic regions and
may act as regulators of gene transcription over long distances
[49], have an activating function on chromatin structure [50], are
sensitive to CpG methylation [51] and have a important role in
developmental processes [43,52,53]. Of two HCNE-containing
elements with enhancer effects implicated with a metabolic role,
one is located within the 7.7 kb methylation window
(chr16:52,371,700–52,379,399). Higher regional methylation of
this enhancer, caused through increased methylatable CpG sites,
on the susceptibility haplotype may impede its action in terms of
enhancer-specific transcription factor recruitment, subsequent
chromatin DNA looping, enhancer-promoter interaction and
enhanceosome formation [51] with subsequent down-regulation
on IRX3 expression. Additionally this HCNE is just over 200 bp 59
of the 900 bp window (chr16:52,378,500–52,379,399). Therefore
the 900 bp peak is within a 2 kb ‘shore’ region of this enhancer
and it may be possible that these ‘Enhancer shores’ act in a similar
fashion to ‘CpG Island shores’ (2 kb either side of Islands) and
regions of low CpG density, which have been identified with more
dynamic DNA methylation effects [54]. Our ChIP-chip data from
skeletal muscle indicate a H3K4me1 signature within the 7.7 kb
region, as well ChIP-Seq data from cell lines confirms a 5K block
of H3K4me1 enrichment completely encapsulated here (http://
bioinformatics-renlab.ucsd.edu/enhancer) (Supplementary Figure
S4) [50] and a recent examination of histone modifications in
pancreatic islets also identified this enhancer marker 1.2 kb wide
over rs8050136 within the region [55]. No evidence of allele-
specific expression was identified from different sources; therefore
whilst the DNA methylation state of the enhancer-including
haplotype may be observed in all tissues, due to being
predominately genetically driven due to CpG-SNPs, the possible
outcome of effect on expression may only be seen in precise cell
types at a precise time and/or environmental-specific manner
[40].
Despite the interesting genomic overlap between the 7.7 kb
region of HSM and the HCNEs identified by Ragvin et al., the
phylogenetically distant zebrafish knock-down of the orthologous
irx3a has reduced pancreatic b insulin- and a glucagon-secreting
cells and increased ghrelin-producing e cells. The role of IRX3 in
pancreatic development is in conflict with the knowledge that most
obese individuals display an increase in pancreatic beta cell mass
as a compensatory response to the peripheral insulin resistance
that co-exists [56] and the knowledge that most previously-
identified obesity genes are involved in neuronally-mediated
central energy balance [42]. However the evidence of functional
enhancer capability of this conserved non-coding region is the
crucial finding, as its downstream target may have changed or
evolved to take on a more complex role over time. It is possible
that IRX3’s role in neurodevelopment of the posterior forebrain in
mammals, including the hypothalamus, may in fact be critical
[54,57,58]. Redressing the previous evidence in favour of FTO
causative role, the fto knock-out mouse targeted exon 2 and 3, only
,1 kb into intron 1 [36], therefore did not remove any of the
putative enhancers. If FTO is involved in the phenotype, the
observed methylation change could affect expression by changing
gene-body methylation or influencing the isoform balance by
modifying exon inclusion or exclusion [59].
Loss or gain of CpG dinucleotides over evolutionary time
leading to a genetically-driven variation in DNA methylation and
subsequent higher variance has been proposed to be a major
driver in evolutionary adaption as well as disease susceptibility
[60,61]. The loss of a CpG site, by deamination of methylated
cytosine, can not only can have considerable influence on regional
Table 4. LD relationship for FTO Association SNPs and rs7202116.
r2
SNP rs1421085 rs17817449 rs8050136 rs3751812 rs9939609 rs7202116* rs9930506
rs1421085 0.927 0.931 0.931 0.931 0.965 0.835
rs17817449 0.963 1 1 1 0.964 0.833
D’ rs8050136 0.965 1 1 1 0.966 0.841
rs3751812 0.965 1 1 1 0.966 0.841
rs9939609 0.965 1 1 1 0.966 0.841
rs7202116* 1 1 1 1 1 0.871
rs9930506 0.963 0.962 0.964 0.964 0.964 1
Results given for D’ and r2 in CEU HapMap population. *Indicates the methylation critical SNP within 900 bp window peak.
doi:10.1371/journal.pone.0014040.t004
Table 5. Pyrosequencing Validation Assay of Bisulphite-
treated DNA – Cytosine Methylation %.
CpG Location
rs8050136
Genotype 52379190* 52379221 52379251 52379254
AA 87 95.1 96.7 49.6
AC 55.7 95.5 97 51.6
CC 11.5 95.1 96.6 49.9
Location of methylated Cytosine of CpG from Hs36 Build within 900 bp 9-
Window.
*CpG-creating SNP rs7202296 dependent.
doi:10.1371/journal.pone.0014040.t005
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methylation [17], but is also an important mechanism in the
formation of transcription factor binding sites [62], such as for p53
that has a role in regulation of insulin resistance [63]. Acquiring
the ability to methylate by a cluster of in-phase alleles within a
regulatory domain could also be selected for, if functionally
significant.
Trans-ethnic studies, especially in genetically diverse African-
derived populations, can be informative in narrowing down the
location of a causative variant in regions of strong LD in the initial
study population [64]. The SNP rs3751812 was the only to confer
significant risk (T allele as on CEU susceptibility haplotype,
Figure 1) in an African-American study [65] and is in a LD block
in two African HapMap populations overlapping the 7.7 kb
window.
In conclusion, we have identified variant-CpG restricted
Haplotype-Specific Methylation within the FTO obesity suscepti-
bility locus. Previous association SNP findings were equivalent
across this region and therefore could be consistent with a
difference in CpG methylation capability being the driving factor
that is inherent to this haplotype. To our knowledge, this is the first
identification of any association with a measureable methylation
difference within a GWA Study SNP association locus. Detailed
analysis of the methylation signal and pyrosequencing validation
indicate the genetic phase of CpG-creating SNPs are a strong
influence in this finding, indicating LD with CpG-creating SNPs as
a relevant consideration in genomic methylation studies. A region
of 7.7 kb drove the most significant haplotype-specific methyla-
tion, and overlies a region containing putative enhancer sequence.
Our observation of increased methylation ability at this enhancer
region may contribute towards reducing the efficiency of this
regulatory element [51]. Thus the investigation of epigenetic
variation may be very useful in narrowing down significant regions
in large LD association blocks and proposing functional hypoth-
eses for subsequent follow-up from GWA studies.
Materials and Methods
Subjects
Whole blood genomic DNA from Caucasian individuals living
in the UK recruited to two pre-existing population cohorts
(coordinated by the same research centre) was used for the
experimental analyses. Forty UK Warren 2 T2D female
participants were selected from trios and had a diagnosis of Type
2 diabetes made by either current prescription of a diabetes-
specific medication or laboratory evidence of hyperglycemia
(World Health Organization definition) [66]. Forty female
participants without diabetes were selected from the Exeter
Family Study of Childhood Health and had normal fasting
glucose and/or HbA1c levels. The mean age of participants was
37 years (standard deviation 6.6) and mean body mass index
29.4 kg/m2 (standard deviation 8.1). Four hypothalamus and ten
prefrontal cortex samples were selected from ‘normal brain’ post-
mortem tissues from the MRC London Brainbank for Neurode-
generative Diseases at the Institute of Psychiatry in London, and
DNA was extracted using standard phenol: chloroform techniques.
Written informed consent was obtained from all participants.
Ethics approval was covered by the Southwest Multicentre
Research Ethics Committee MREC/00/6/55 (UK Warren 2
T2D samples) and Royal Devon and Exeter Healthcare NHS
Trust Study 1104 (Exeter Family Study). Post-mortem brain tissue
subjects are approached in life for written consent for brain
banking, and all tissue donations are consented, collected and
stored following legal and ethical guidelines (NHS reference
number 08/MRE09/38). The HTA license number for the
brainbank is 12293.
Array Design
The Nimblegen array comprised of 387,835 50-75mer Probes
divided into 122 regions covering 37,037,978 bases of the genome.
(080314_HG18_PA_Tiling). This was targeted at all then known
T2D Association Loci (20 regions: +/2 60 kb around gene or LD
block around association SNP in non-genic regions), Monogenic
Obesity & Diabetes (13 genes), the T2D Chromosome 1q linkage
region (1q21-24: 148.4–171.3 Mb) comprising 22.8 Mb, identified
in multi-continental populations including European, East-Asian,
Native-American, and African-American [67]), all Known Im-
printed Genes & Imprinting Control Regions from the Imprinted
Gene and Parent-Of-Origin Effect Database (www.otago.ac.nz/
IGC) gene or control region +/2 5000 bp numbering 82 loci [23]
which includes confirmed human, as well as regions syntenic to
mouse imprinted loci which have not yet been confirmed in
human. Finally, a miscellaneous group of nine loci including
Coronary Artery Disease and Stature, hyperuricaemia association
regions and the PPARGCA1 gene [68] were included. For full list
see Supplementary Table S1. All coordinates are for genome build
NCBI Hs36.1/HG18.
MeDIP
The protocol was modified from Weber et al. [20] as previously
described. 1.7 mg DNA is sonicated to produce 300-700 bp
fragments. 500 ng DNA is set aside as the ‘input’ control and
the remaining 1.2 mg is denatured to become the ‘MeDIP’
fraction. Each denatured DNA sample was incubated with 5MeC-
mAb and added to DynabeadsH (Invitrogen). ‘MeDIP’ and ‘input’
DNA are then amplified using the Sigma-Aldrich GenomePlexH
Whole Genome Amplification kit. Quality control for MeDIP
enrichment efficiency is performed by Q-PCR comparison of two
differentially methylated regions of the genome (selected from the
Human Epigenome Project primer sequences; methylated locus
ID: 6583, unmethylated: 8804; available from www.epigenome.
org) with a minimum of a 3 cycle lag for the input compared to the
MeDIP fraction for the methylated locus.
Table 6. Primate Comparison for 900 bp CpG-creating SNPs.
rs7206629 rs7202116 rs7202296
Homo sapiens …TTGGTYGAAGT… …TAAACRTCTTT… …AAGCCRATAAA…
Pan troglodytes …TTGGTCGAAGT… …TAAACATCTTT… …AAGCCAATAAA…
Pongo pygmaeus …TTGGTCGAAGT… …TAAACATCTTT… …AAGCCAATAAA…
Macaca mulatta …TTGGCCGAAGT… …TAAACATCTTT… …AAGCCAATAAA…
SNPs rs7206629 at 52378914, rs7202116 at 52379116 and rs7202296 at 52379191 in the human sequence are shown in bold.
doi:10.1371/journal.pone.0014040.t006
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Quality Control
Intensity and Spatial Plots were drawn. Lowess Normalisation
was used to smooth out data variation arising from non-linear
responses during labelling, hybridisation, or scanning to the two
different dye colours. Quantile Normalisation was performed to
correct for variation in probe level intensities between arrays. The
normalised and raw data are available from GEO (Gene
Expression Omnibus, NCBI) under the accession number
GSE20553.
Estimation of Absolute Methylation
Array IP/intensity is assumed to be proportional to the density
of methylated CpGs. A Bayesian estimation of methylation within
fragments of varied CpG density is made using BATMAN
(described in detail in Down et al.), with the data output resulting
in 100 bp window methylation scores [69]. The algorithm was run
individually on each sample.
Differential Methylation Calling
BATMAN reported methylation values for 100 bp regions,
called ‘‘proxies’’, within larger regions of interest (ROI) varying
from 500 to 4000 bp in length. We aimed to call DMRs at the
length scale of ROIs to confer with normal methylation
consistency that occurs over 500–1000 bp. However, we also
observed that some proxies within ROIs exhibited significant
variation in methylation. We therefore sought an algorithm that
would call DMRs at the length of ROIs, but would use the
methylation values of the individual proxies within a ROI rather
than an average across all proxies. We adapted an empirical
Bayesian method [70], where the case/control status of a sample s
(Ps = 1 for case, Ps = 0 for control) is modelled as
EPsb~h{1 azp~1nproxmpsbpð Þ
where h is the logit-link function (logistic regression), nprox is the
number of proxies in the ROI, and mps is the methylation value
for proxy p in sample s. Because the number of samples is not large
(,number of proxies) we simplify the problem by assuming that all
regression coefficients are drawn from an underlying distribution
with mean zero and finite variance s2. The null hypothesis
,Ho : b1~b2~:::~bnprox~0
then becomes Ho: s2=0 [70]. The Bayesian algorithm reports p-
values for rejecting the null-hypothesis for each ROI. To correct
for multiple testing, we estimated the False Discovery Rate (FDR)
using two approaches: the q-value approach [71] and a
permutation-based approach whereby sample labels were permut-
ed a large number of times (.1000).
LD Block Methylation and Sliding Windows Analysis
Linkage Disequilibrium blocks around genotyped susceptibility
genes were defined as per Gabriel et al. [18], as implemented in
HAPLOVIEW v.4.1 [72]. At each block, subjects were grouped
by genotype without reference to case or control status, for each
T2D susceptibility SNP. Average methylation score was calculated
per block by summating scores for all BATMAN windows within
in it and dividing by the number of windows. Non-parametric
(Kruskal-Wallis) and parametric (Linear Regression) tests gener-
ated p value statistics for the mean methylation score with respect
to genotype status. Permutation empirical p-values were calculated
by retaining observed methylation scores and shuffling genotype
assignment 10,000 times.
A sliding windows analysis was performed across these LD
blocks using 100 bp BATMAN methylation output windows,
similar to that used in the context of contiguous SNP haplotypes
[73]. Starting with a window size of one and moving one window
along per calculation across the entire block, Kruskal–Wallis and
Linear Regression analyses were performed for the genotype
groups with respect to methylation scores. Window size was
increased by one on each pass and the analysis repeated, until the
window size equalled the entire LD block. The resulting p-values
were outputted and plotted at the midway point for each window.
Detection of both non-linear and a biologically plausible linear
association, between genotype and methylation status provides
robust support to the significant relationship at the FTO LD block
(Supplementary Video S1 and S2). Sliding windows analysis,
statistical calculation, and permutation scripts were written with
the R package [74].
Pyrosequencing
Primers were designed using the Biotage PSQ assay design
software 1.06 ( Biotage). Primer sequences and PCR reaction
details are available from the authors on request. The reaction was
performed on the Biotage PSQ HS96 instrument, as per
manufactures instructions.
Bioinformatic Analysis
All genome co-ordinates are given for NCBI Build Hs36.1/
UCSC hg18. Scripts for analysis and mining of non-ancestral
methylation creating SNPs from dbSNP were written in Perl.
Median Network Haplotype Analysis
Analysis was performed on phased SNP data from HapMap
Phase II SNP (420 phased haplotypes from the CEU, YRI & ASN
populations), plus the addition of the inferred ancestral haplotype
from ENSEMBL SNP data/dbSNP, for the FTO susceptibility LD
Block with the NETWORK 4.5.1.0 software [26] ( 2008 Fluxus
Technology Ltd). Modelling the hypermutability of CpG transi-
tion between 2x to 15x baseline rate did not change tree pattern,
only shortened intervening branches with increasing rate (Supple-
mentary Figure S3 is shown for 15x) [75,76].
RNA-Seq Analysis
RNA-Seq data generated by an Illumina Genome Analyser
from RNA derived from ,24 hr post-mortem Cerebellum tissue
samples of six anonymous unrelated donor males was available
from the paper of Wang et al. [32]. These data were aligned using
TopHat 1.0, which incorporates the Bowtie aligner and addition-
ally generates splice junction reads [77]. SAM output files were
visualised with the Integrative Genomics Viewer (version 1.4.01,
http://www.broadinstitute.org/igv).
ChIP-Chip
Chromatin Immunoprecipitation for H3K4me1, H3K4me2,
H3K4me3, CTCF, H3K9me1 and H3K9me2 was performed on
the same T2D designed arrays in normal human skeletal muscle
cells, as part of a larger experiment utilising a standard protocol
[78]. ChIP Peaks were located by MPeak [79]. Duplicates were
performed for all, with 90–95% agreement between replicates for
all antibodies.
Supporting Information
Figure S1 FTO HapMap CEU Linkage Disequilibrium.
Location of FTO Association LD block indicated by Red
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Rectangle, as visualised in HAPLOVIEW with LD block as
defined by Gabriel et al. [18].
Found at: doi:10.1371/journal.pone.0014040.s001 (8.73 MB TIF)
Figure S2 Linear Regression Slope viewed with Linear Regres-
sion p-values. Plot of Negative Slope of Linear Regression for the 9
window across the LD block (below) indicating Negative Slope at
regions of p-value peaks (above).
Found at: doi:10.1371/journal.pone.0014040.s002 (0.43 MB TIF)
Figure S3 Median-Joining Network of FTO susceptibility region
haplotypes. Evolutionary relations of the 60 distinct haplotypes
from 420 phased haplotypes from HapMap phased haplotypes
(CEU, YRI and ASN) plus the Ancestral haplotype. Blue
(methylation capable haplotypes within the 900 bp narrow peak
with possession of the rs7202116 G allele) and Yellow (non-
methylation capable) circles are proportional in size to the number
of copies of that haplotype. Lines joining haplotypes are
proportional to the number of mutational events separating them.
Red nodes are unseen haplotypes, within this sampled set, that are
inferred by the MJ algorithm [26]. The thick blue outlined circle
represents the haplotype identical to entire CEU susceptibility
haplotype indicated in Figure 1 (made up of 49 CEU, 6 YRI & 9
ASN haplotypes).
Found at: doi:10.1371/journal.pone.0014040.s003 (8.48 MB TIF)
Figure S4 Enhancer Prediction in 7.7 kb Broad Peak. Enhancer
prediction within the Haplotype-Specific Methylation broad peak
window of 7.7 kb. Enhancer prediction from H3K4me1 Chip-Seq
from Heintzmans et al. in red (http://bioinformatics-renlab.ucsd.
edu/enhancer) [50]. Location of Ragvin et al. predicted enhancer
(black with red border) and the H3K4me1 data from skeletal
muscle indicated in the H3K4me1_SO2 row. Blue rectangle
indicates 900 bp differential methylation region window that lies
in the shore region of the Ragvin et al. enhancer. CpG creating
SNPs in the 900 bp window are indicated with red rectangles.
Highest Vertebrate PhastCons Conserved Elements LOD score
[81] is underlined in red.
Found at: doi:10.1371/journal.pone.0014040.s004 (6.64 MB TIF)
Table S1 Array Design.
Found at: doi:10.1371/journal.pone.0014040.s005 (0.05 MB
XLS)
Video S1 Sliding windows for Kruskal-Wallis analyses across
FTO LD block.
Found at: doi:10.1371/journal.pone.0014040.s006 (1.05 MB
MOV)
Video S2 Sliding windows for Linear Regression analyses across
FTO LD block.
Found at: doi:10.1371/journal.pone.0014040.s007 (0.72 MB
MOV)
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